This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human TGF-beta 3, Animal-Free Protein
catalog :
Qk054-0500
quantity :
500 ug (also 50 ug)
price :
3893 USD
product information
master code :
Qk054
SKU :
Qk054-0500
product name :
Recombinant Human TGF-beta 3, Animal-Free Protein
unit size :
500 ug (also 50 ug)
description :
The Recombinant Human TGF-beta 3, Animal-Free Protein from R&D Systems is derived from E. coli. The Recombinant Human TGF-beta 3, Animal-Free Protein has been validated for the following applications: Bioactivity.
target :
TGF-beta 3
category :
Proteins and Enzymes
buffer :
Lyophilized from acetonitrile/TFA
conjugate :
Unconjugated
species :
Human
observed molecular weight :
Dimeric TGF┐▀3 protein only
theoretical molecular weight :
12.7 kDa (monomer), 25.4 kDa (dimer)
details of functionality :
No significant difference between EC50 of reference and test lots
endotoxin note :
<0.10 EU per 1 ╡g of the protein by the LAL method.
accessionNumbers :
P10600.1
applications :
Bioactivity
source long :
E. coli -derived human TGF-beta 3 protein
source short :
E. coli
USD :
3893 USD
alt names :
ARVD, ARVD1, FLJ16571, LDS5, RNHF, TGFB3, TGFbeta 3, TGF-beta3, TGF-beta-3, transforming growth factor beta-3, transforming growth factor, beta 3
storage :
Store lyophilized protein between -20 and -80 ░C until the date of expiry. Avoid freeze-thaw cycles.
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
questions and comments
